ATE406452T1 - Retrovirale vektoren - Google Patents

Retrovirale vektoren

Info

Publication number
ATE406452T1
ATE406452T1 AT97909438T AT97909438T ATE406452T1 AT E406452 T1 ATE406452 T1 AT E406452T1 AT 97909438 T AT97909438 T AT 97909438T AT 97909438 T AT97909438 T AT 97909438T AT E406452 T1 ATE406452 T1 AT E406452T1
Authority
AT
Austria
Prior art keywords
dependent
hiv
rev
transcription unit
provirus
Prior art date
Application number
AT97909438T
Other languages
English (en)
Inventor
Susan Mary Kingsman
Alan John Kingsman
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE406452T1 publication Critical patent/ATE406452T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developing Agents For Electrophotography (AREA)
AT97909438T 1996-10-17 1997-10-17 Retrovirale vektoren ATE406452T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9621679.1A GB9621679D0 (en) 1996-10-17 1996-10-17 Improved retroviral vectors

Publications (1)

Publication Number Publication Date
ATE406452T1 true ATE406452T1 (de) 2008-09-15

Family

ID=10801597

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97909438T ATE406452T1 (de) 1996-10-17 1997-10-17 Retrovirale vektoren

Country Status (8)

Country Link
US (2) US20020141978A1 (de)
EP (1) EP0931157B1 (de)
JP (1) JP2001502904A (de)
AT (1) ATE406452T1 (de)
AU (1) AU4712497A (de)
DE (1) DE69738944D1 (de)
GB (2) GB9621679D0 (de)
WO (1) WO1998017817A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3988799A (en) 1998-05-13 1999-11-29 Genetix Pharmaceuticals, Inc. Novel lentiviral packaging cells
WO1999067400A1 (en) 1998-06-24 1999-12-29 Musc Foundation For Research Development Tissue-specific and target rna-specific ribozymes
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
DE10056747A1 (de) 1999-11-16 2001-05-31 Yiming Shao Das Genom des HIV-1 Intersubtyps (C/B') und seine Anwendungen
EP1702983A3 (de) 2000-04-13 2007-01-10 Medical University of South Carolina Gewebespezifische und pathogenspezifische giftige Verbindungen, Ribozyme, DNAzyme und Antisenseolinukleotide sowie Anwendungen dafür
US20120294889A1 (en) * 2010-11-12 2012-11-22 Paxvax, Inc. Chimeric Flavivirus Vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306631A (en) * 1987-08-21 1994-04-26 University Of Colorado Foundation, Inc. Compositions and method for inhibition of HIV production
US6544771B1 (en) * 1987-12-11 2003-04-08 Cell Genesys, Inc. Retroviral gene therapy vectors and therapeutic methods based thereon
EP0588914A1 (de) * 1991-05-29 1994-03-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Eukaryotische expressionsvektoren mit steuerung der rns-prozessierung
WO1995030755A1 (fr) * 1994-05-10 1995-11-16 Hisamitsu Pharmaceutical Co., Inc. Vecteur recombinant du virus de l'immunodeficience humaine et procede pour sa production

Also Published As

Publication number Publication date
GB2331989A (en) 1999-06-09
WO1998017817A1 (en) 1998-04-30
AU4712497A (en) 1998-05-15
EP0931157A1 (de) 1999-07-28
GB9904143D0 (en) 1999-04-14
EP0931157B1 (de) 2008-08-27
GB9621679D0 (en) 1996-12-11
US20020141978A1 (en) 2002-10-03
DE69738944D1 (de) 2008-10-09
US20060024279A1 (en) 2006-02-02
GB2331989B (en) 2000-09-27
JP2001502904A (ja) 2001-03-06

Similar Documents

Publication Publication Date Title
GB2331522B (en) Lentiviral vectors
DE69534733D1 (de) NEUARTIGE AUF p53 ANSPRECHENDE GENE
Ling et al. The solitary long terminal repeats of ERV-9 endogenous retrovirus are conserved during primate evolution and possess enhancer activities in embryonic and hematopoietic cells
WO2001071042A3 (en) Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof
NO20001497L (no) Ekspresjon av endogene gener ved ikke-homolog rekombinasjon av en vektorkonstrukt med cellulært DNA
EP0385558A3 (de) Materialien und Verfahren für "genome walking"
Klasens et al. Inhibition of polyadenylation by stable RNA secondary structure
ATE510920T1 (de) Dna-sequenzen zur regulation der transkription
ATE406452T1 (de) Retrovirale vektoren
Ioshikhes et al. Nucleosomal DNA sequence database.
Schoner et al. Enhanced expression of mouse dihydrofolate reductase in Bacillus subtilis
DE3786586D1 (de) Genexpressionssystem.
DE69739346D1 (de) Gereinigtes sr-p70 protein
ATE272711T1 (de) Neuartige expressionsvektoren
DE69323199T2 (de) Gen für die ataxia-telangiectasia komplementationsgruppe d
SE8604636D0 (sv) Sett att uttrycka gener med hjelp av bacillus brevis
ATE72837T1 (de) Vielfach amplifizierbare vektoren fuer hohe expression exogener dns.
HUP0004857A2 (hu) T. variabilisból származó D-aminosav oxidáz promótere
Mischiati et al. Characterization of a major histocompatibility complex class II X-box-binding protein enhancing tat-induced transcription directed by the human immunodeficiency virus type 1 long terminal repeat
ATE259421T1 (de) Dna-virus-vektoren und verfahren zu ihrer herstellung
WO2002029101A3 (en) Methods for cloning, sequencing and expressing genes from complex microbial populations
CA2289907A1 (en) Eukaryotic and retroviral antisense initiator elements
Peberdy Genetic engineering in relation to enzymes.
DK561889A (da) Ekspressionsforstaerker samt anvendelse heraf til forhoejelse af udbyttet ved ekspression af rekombinante gener
EP0962533A3 (de) Auf Zucker reagierende Enhancer-Sequenzen aus alpha-Amylasegenen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0931157

Country of ref document: EP